- Home
- VOC vs CGTX Comparison
VOC vs CGTX Comparison
Compare VOC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOC
- CGTX
- Stock Information
- Founded
- VOC 2010
- CGTX 2007
- Country
- VOC United States
- CGTX United States
- Employees
- VOC N/A
- CGTX N/A
- Industry
- VOC Oil & Gas Production
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- VOC Energy
- CGTX Health Care
- Exchange
- VOC Nasdaq
- CGTX Nasdaq
- Market Cap
- VOC 48.6M
- CGTX 20.5M
- IPO Year
- VOC 2011
- CGTX 2021
- Fundamental
- Price
- VOC $2.94
- CGTX $0.53
- Analyst Decision
- VOC
- CGTX Strong Buy
- Analyst Count
- VOC 0
- CGTX 5
- Target Price
- VOC N/A
- CGTX $5.63
- AVG Volume (30 Days)
- VOC 85.3K
- CGTX 1.9M
- Earning Date
- VOC 01-01-0001
- CGTX 08-07-2025
- Dividend Yield
- VOC 21.70%
- CGTX N/A
- EPS Growth
- VOC N/A
- CGTX N/A
- EPS
- VOC 0.63
- CGTX N/A
- Revenue
- VOC $11,917,424.00
- CGTX N/A
- Revenue This Year
- VOC N/A
- CGTX N/A
- Revenue Next Year
- VOC N/A
- CGTX N/A
- P/E Ratio
- VOC $4.61
- CGTX N/A
- Revenue Growth
- VOC N/A
- CGTX N/A
- 52 Week Low
- VOC $2.44
- CGTX $0.22
- 52 Week High
- VOC $5.69
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- VOC 48.85
- CGTX 67.18
- Support Level
- VOC $2.76
- CGTX $0.29
- Resistance Level
- VOC $2.92
- CGTX $0.34
- Average True Range (ATR)
- VOC 0.11
- CGTX 0.03
- MACD
- VOC 0.01
- CGTX 0.01
- Stochastic Oscillator
- VOC 41.38
- CGTX 92.26
About VOC VOC Energy Trust Units of Beneficial Interest
VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.